Evidence map›Paper›PMID 29026866›Full record

ArticleOpen forum infectious diseases2017

A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant

Oryan Henig, Eric Cober, Sandra S Richter, Federico Perez, Robert A Salata, Robert C Kalayjian, Richard R Watkins, Steve Marshall, Susan D Rudin, T Nicholas Domitrovic and 9 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Carbapenem-resistantOpen forum infectious diseases · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 1 country.

Oryan HenigDepartment of Medicine, University of Michigan, Ann Arbor; Departments of.
Eric CoberInfectious Diseases and.
Sandra S RichterLaboratory Medicine, Cleveland Clinic, Ohio.
Federico PerezResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
Robert A SalataDivision of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Robert C KalayjianDepartment of Medicine, MetroHealth Medical Center, Cleveland, Ohio.
Richard R WatkinsDepartment of Internal Medicine, Northeast Ohio Medical University, Rootstown.
Steve MarshallResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
Susan D RudinResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
T Nicholas DomitrovicResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
Andrea M HujerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
Kristine M HujerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania.
Scott EvansDepartment of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts.
Vance G FowlerDivision of Infectious Diseases and.
Robert A BonomoResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Ohio.
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill.
Keith S KayeDepartment of Medicine, University of Michigan, Ann Arbor; Departments of.
Antibacterial Resistance Leadership Group
Louis Stokes Cleveland VA Medical Center · USUniversity of Michigan–Ann Arbor · USUniversity School · USCancer Research And Biostatistics · USCleveland Clinic · USMetroHealth Medical Center · USNortheast Ohio Medical University · USOffice of Infectious Diseases · USUniversity of North Carolina at Chapel Hill · USUniversity of Pittsburgh · US

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat SuperbugsR01AI119446 · NIAID · WAYNE STATE UNIVERSITY · PI LI, JIAN, POGUE, JASON MICHAEL · 2015 to 2019
$5.0M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
Mentoring Patient Oriented Research in Antibiotic-Resistant BacteriaK24AI093969 · NIAID · DUKE UNIVERSITY · PI FOWLER, VANCE G. · 2011 to 2020
$1.6M
Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445k
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–
BLRD VA I01 BX001974NCATS NIH HHS UL1 TR001863NIAID NIH HHS K24 AI093969NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R01 AI119446NIAID NIH HHS R21 AI114508NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

backgroundThis study was performed to characterize the epidemiology, management, and outcomes of skin and soft tissue infection (SSTI) and colonization due to carbapenem-resistant

methodsPatients from the Consortium on Resistance Against Carbapenem in

resultsOne hundred forty-two patients were included: 62 had SSTI (44%) and 56% were colonized. Mean age was 61 years, and 48% were male: median Charlson score was 3 (interquartile range, 1-5). Forty-eight percent of patients were admitted from long-term care facilities (LTCFs), and 31% were from the community. Two strain types (ST258A and ST258B) were identified (73% of 45 tested). Carbapenemase genes were detected in 40 of 45 isolates (

conclusionsPatients admitted from LTCFs with CRE SSTI were less likely to undergo surgical intervention. Sixteen percent of the patients died, and approximately 50% of survivors required more intensive care upon discharge. These findings suggest a unique, impactful syndrome within the CRE infection spectrum. Further studies are needed to assess the role of surgical debridement in management of CRE-SSTI, particularly among LTCF residents.

Indexed as

carbapenem-resistant EnterobacteriaceaeKlebsiella pneumoniaeST258surgical site infectionswound infection

Identifiers

PMID29026866
PMCPMC5629814
OpenAlexW2766180851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.